[ | E-mail ] Contact: Ronald Rogersrrogers@myriad.com 801-584-3065Myriad Genetics, Inc.@myriadgenetics Tumor BRACAnalysis CDx identifies 44 percent more candidates for PARP therapy SALT LAKE CITY, Utah, Sept. 29, 2014 Myriad Genetics, Inc. (Nasdaq: MYGN) today announced that its Tumor…
Source:Myriad presents tumor BRACAnalysis CDx study at ESMO
Monday, September 29, 2014
Myriad presents tumor BRACAnalysis CDx study at ESMO
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment